Who
Phillip B. Donenberg
Director
Company insider
Files Form 4 as: Director, Sensei Biotherapeutics; Director, Tectonic Therapeutic; Director, Taysha Gene Therapies; SVP and CFO, Depomed; Chief Financial Officer, AveXis; Chief Financial Officer, CervoMed; Sr VP of Finance, CFO, Secy, ANI Pharmaceuticals.
In numbers
- Trades disclosed
- 67
- Buys
- 10
- Sells
- 0
- Bought
- $164K
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 3
- First trade
- 16 Mar 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | Sensei Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTH Faeth Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —21,335 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,671 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,671 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —21,335 at $0.00 | filing |
| 10 Apr 2026filed 14 Apr 2026 | Sensei Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,100 at $0.00 | filing |
| 10 Apr 2026filed 14 Apr 2026 | FTH Faeth Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,100 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | Sensei Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,900 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | FTH Faeth Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,900 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —113,246 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —56,623 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,760 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,440 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —49,220 at $0.00 | filing |
| 16 Aug 2023filed 16 Aug 2023 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Bought | $100K111,111 at $0.90 | filing |
| 22 Jun 2023filed 26 Jun 2023 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,200 at $0.00 | filing |
News
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETANIP · manilatimes.net · 23 Oct 2026Head-To-Head Survey: Taysha Gene Therapies (NASDAQ:TSHA) vs. MediWound (NASDAQ:MDWD)TSHA · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Phillip B. Donenberg; 2 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.